Beyondspring (BYSI) has released an update.
BeyondSpring Inc., a biopharmaceutical company, has successfully filed a registration statement with the SEC for the issuance of over 1.2 million ordinary shares, as detailed in a prospectus supplement dated June 12, 2024. This move, executed in accordance with a Securities Purchase Agreement, aims to strengthen the company’s financial position. Legal opinions confirm that the shares, once issued and paid for, will be fully legitimate and non-assessable under Cayman Islands law.
For further insights into BYSI stock, check out TipRanks’ Stock Analysis page.
